comprehensive -WSS

comprehensive

author：leisure time 2025-09-28 01:16:40 - browse：9633

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Plane’s emergency slide plummets from sky, hits Chicago home

leisure time

WSS

Orchard's therapy for neuron disease in children wins FDA approval

U.K. researchers warn about biases in medical devices, algorithms

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Nurses recount patients attacks

explore

comprehensive

focus

In Memoriam: Notable people who died in 2023

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Novavax promises a turnaround & Lilly roils the obesity market

New warning issued for rebooking air travel after delays, cancellations

Alkermes shareholders re

Intermittent fasting comes with a heart risk? Not so fast

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Gene editing the human germline: What are the risks?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Norman Reedus' Daryl Dixon

hotspot

AstraZeneca to buy developer of next

Why some people catch Covid but never get sick

Ebola public health emergency is over, WHO declares

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

Asbestos, a deadly carcinogen, banned by EPA

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

knowledge

focus

leisure time

leisure time